1. Home
  2. HMN vs ORKA Comparison

HMN vs ORKA Comparison

Compare HMN & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horace Mann Educators Corporation

HMN

Horace Mann Educators Corporation

HOLD

Current Price

$43.17

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$32.95

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HMN
ORKA
Founded
1945
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
HMN
ORKA
Price
$43.17
$32.95
Analyst Decision
Buy
Strong Buy
Analyst Count
5
11
Target Price
$46.75
$49.73
AVG Volume (30 Days)
260.0K
486.5K
Earning Date
02-03-2026
03-05-2026
Dividend Yield
3.24%
N/A
EPS Growth
57.26
N/A
EPS
3.90
N/A
Revenue
$1,701,400,000.00
N/A
Revenue This Year
$7.50
N/A
Revenue Next Year
$2.84
N/A
P/E Ratio
$11.07
N/A
Revenue Growth
6.66
N/A
52 Week Low
$38.76
$5.49
52 Week High
$48.33
$36.51

Technical Indicators

Market Signals
Indicator
HMN
ORKA
Relative Strength Index (RSI) 53.48 50.81
Support Level $42.03 $31.15
Resistance Level $45.13 $35.46
Average True Range (ATR) 1.09 1.98
MACD 0.23 -0.33
Stochastic Oscillator 77.16 28.05

Price Performance

Historical Comparison
HMN
ORKA

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are 403(b) tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Share on Social Networks: